TRML - Tourmaline Bio, Inc.

QQQ $ 633.65 $ 0.00 (0 %)

DIA $ 474.88 $ 0.00 (0 %)

SPY $ 684.51 $ 0.00 (0 %)

TLT $ 90.32 $ 0.00 (0 %)

GLD $ 369.39 $ 0.00 (0 %)

Previous Close

$ 47.98

Open

$ 47.98

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

-- - --

52 Week Range

$ 11.56 - $ 48.27

Volume

783,730

Average Volume

Market Cap

1.23B

Beta (5Y Monthly)

$ 1.64

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-02-2025	03-31-2025	10-Q
3	03-13-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-19-2024	12-31-2023	10-K
8	11-14-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-31-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-17-2022	12-31-2021	10-K
16	11-12-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	06-14-2021	03-31-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Suspends Overweight Rati...
10/29/2025 13:54:18

Cantor Fitzgerald suspends Overweight rating on Tourmaline Bio (NASDAQ:TRML).

this-new-mountain-finance-analyst-turns-bearish-here-are-top-3-downgrades-for-monday

This New Mountain Finance Analyst Turns Be...
09/15/2025 11:15:08

BMO Capital Downgrades Tourmaline Bio to M...
09/15/2025 10:16:15

BMO Capital analyst Kostas Biliouris downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and raises th...

Piper Sandler Downgrades Tourmaline Bio to...
09/11/2025 18:20:52

Piper Sandler analyst Yasmeen Rahimi downgrades Tourmaline Bio (NASDAQ:TRML) from Overweight to Neutral and lowers the price...

Truist Securities Downgrades Tourmaline Bi...
09/10/2025 13:15:57

Truist Securities analyst Robyn Karnauskas downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price tar...

Guggenheim Downgrades Tourmaline Bio to Ne...
09/10/2025 12:46:55

Guggenheim analyst Yatin Suneja downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price target from...

HC Wainwright & Co. Downgrades Tourmaline ...
09/10/2025 11:00:50

HC Wainwright & Co. analyst Yi Chen downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

Chardan Capital Downgrades Tourmaline Bio ...
09/10/2025 10:21:57

Chardan Capital analyst Daniil Gataulin downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

LifeSci Capital Downgrades Tourmaline Bio ...
09/09/2025 19:53:54

LifeSci Capital analyst Rami Katkhuda downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and announce...

Jefferies Downgrades Tourmaline Bio to Hol...
09/09/2025 19:36:18

Jefferies analyst Roger Song downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price target from $64 t...

dow-surges-over-100-points-korn-ferry-earnings-top-views

Dow Surges Over 100 Points; Korn Ferry Ear...
09/09/2025 17:30:07

12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 17:06:26

tourmaline-bio-qmmm-holdings-teck-resources-and-other-big-stocks-moving-higher-on-tuesday

Tourmaline Bio, QMMM Holdings, Teck Resour...
09/09/2025 14:36:32

Wedbush Downgrades Tourmaline Bio to Neutr...
09/09/2025 12:28:06

Wedbush analyst Laura Chico downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Neutral and maintains the price targe...

novartis-to-expand-heart-drug-portfolio-with-14-billion-tourmaline-bio-acquisition

Novartis To Expand Heart Drug Portfolio Wi...
09/09/2025 12:10:32

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardi...

12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 12:09:28

why-nebius-group-shares-are-trading-higher-by-around-50-here-are-20-stocks-moving-premarket

Why Nebius Group Shares Are Trading Higher...
09/09/2025 10:50:28

Novartis Agrees To Acquire Tourmaline Bio ...
09/09/2025 09:29:57

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option fo...

Reported Sunday, Tourmaline Bio Presents T...
09/02/2025 07:40:26

Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across cli...

Chardan Capital Maintains Buy on Tourmalin...
08/14/2025 16:16:03

Chardan Capital analyst Daniil Gataulin maintains Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $70 price target.